8-K: Calidi Biotherapeutics Executes 1-for-16 Reverse Stock Split

Calidi Biotherapeutics announced a 1-for-16 reverse stock split, effective July 30, 2026, to increase its share price and maintain NYSE American listing.

Summary

• Calidi Biotherapeutics, Inc. has completed a 1-for-16 reverse stock split of its common stock.
• This action was taken to increase the per-share trading price and ensure continued listing on the NYSE American.
• The reverse stock split was approved by stockholders on June 12, 2026, and became effective on July 30, 2026.
• Trading on a split-adjusted basis began on July 31, 2026, under the existing symbol CLDI.
• A new CUSIP number (320703 507) has been assigned.
• Fractional shares were rounded up to the nearest whole share, with no cash paid for fractional interests.
• Outstanding equity awards were also adjusted to reflect the split.
• The company's authorized capital stock, including preferred stock, remains unchanged.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it addresses a critical listing requirement, its success is not guaranteed and it does not fundamentally alter the company's business operations or financial performance.

Positives

• Proactive measure to increase share price and support continued listing on NYSE American.
• No fractional shares were issued; instead, they were rounded up, simplifying shareholding.
• Percentage ownership and voting power for most stockholders remain unchanged.

Negatives

• The company cannot guarantee that the reverse stock split will achieve its desired effects or that these effects will be sustained.
• Potential for minor changes in percentage ownership due to fractional share rounding.

Risks

• Risk of not satisfying continued listing standards on the NYSE American if the share price does not increase sufficiently.
• Uncertainty regarding the sustained effectiveness of the reverse stock split in boosting the share price.

Future Outlook

The company cannot provide assurance that the reverse stock split will achieve its intended effects on the share price or that these effects will be sustained.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common strategy for companies facing delisting risks due to low share prices, aiming to meet exchange requirements and improve investor perception, though their long-term effectiveness can vary.

Stakeholder Impact

• Shareholders: Most will see their number of shares reduced by a factor of 16, but their proportional ownership remains largely the same. Fractional shares were rounded up.
• Creditors: No direct impact mentioned.
• Employees: Holders of equity awards will have their awards adjusted to reflect the split.
• Suppliers: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• Monitor the trading price of CLDI to assess the effectiveness of the reverse stock split in maintaining NYSE American listing standards.

Key Dates

Recommendation

The reverse stock split is a defensive measure to maintain listing, not a growth catalyst. While it addresses an immediate risk, the underlying business performance will ultimately drive the stock price. Investors should hold to observe the impact and future operational developments.

Keywords

Reverse Stock Split, Calidi Biotherapeutics, NYSE American, Stock Listing, Capital Stock, Common Stock, Share Price, Corporate Action